Harikrishna Nakshatri
Marian J Morrison Professor of Breast Cancer Research, Professor of Surgery, Biochemistry and Molecular BiologySurgery and Cancer Center
ude[dot]ui[at]tahskanh
Enhancing hormone therapy and chemotherapy sensitivity of breast cancer
My laboratory was the first to report constitutive activation of NF-κB in estrogen receptor negative breast cancer. The current focus is on genomic aspects of anti-estrogen resistance, mechanisms of organ-specific metastasis and heterogeneity in normal breast. These studies have resulted in three patents, another pending and establishment of a start-up company. For example, NF-kB inhibitor developed in the lab entered phase I clinical trial for leukemia. FOXA1 has been identified as a biomarker for estrogen receptor positive breast cancer. Several cell line resources have been developed in the lab, which are being used worldwide for drug discovery purpose.